



IGH Reflex Panel for Multiple Myeloma



IGH rearrangements are disease-initiating events in up to 40% of multiple myeloma (MM) cases, as well as the MM precursor, monoclonal gammopathy of undetermined significance (MGUS).¹ These rearrangements result in fusions with several recurrent partner genes. Empire Genomics' IGH Reflex FISH Panel is designed to detect 4 major IGH fusions found in MM:

IGH/MAF (IGH-MAF-SPLIT-20-GO-R)



The cryptic IGH/MAF fusion subjects MAF to IGH's powerful enhancer, resulting in MAF upregulation in plasma cells. The abnormality occurs in 5% of MM and 1-5% of MGUS patients. It's considered an early stage biomarker for the disease.²



IGH/MAFB (IGH-MAFB-SPLIT-EXT-20-GO-R)



IGH/MAFB fusion is found in about 1% of MM.³ Consistent with other IGH/MAF family fusions, it's considered a high-risk MM marker.³ The fusion upregulates MAFB expression, which promotes transformation of fibroblasts and enhances tumor cell proliferation.⁴





CCND1/IGH (CCND1-IGH-SPLIT-20-OG-R)



CCND1 is found fused to IGH in 15-20% of MM patients, representing the most frequent rearrangement in the disease. The fusion is usually balanced, and occurs alongside monosomy 13 in about 25% of cases. It's considered a standard risk alteration in MM.³

FGFR3/IGH (FGFR3-IGH-SPLIT-20-OG-R)



IGH/FGFR3 fusion occurs in 15–20% of MM patients. It is frequently detected alongside chromosome 13q deletions. The percentage of plasma cells harboring IGH/FGFR3 increases significantly with disease progression, evidence that the alteration drives MM development.⁵

1. Kim G, *et al.* (2014) *Genes, Chromosomes and Cancer* 53.6: 467-474.
2. *Atlas of Genetics & Cytogenetics in Oncology & Hematology* (2018). DOI: 10.4267/2042/70210
3. Saxe D, *et al.* (2019) *International Journal of Laboratory Hematology* 41.1: 5-14.
4. Qiang YW, *et al.* (2018) *BMC Cancer* 18.1: 724.
5. Kalff A & Spencer A (2012) *Blood Cancer Journal* 2.9: e89-e89

For In Vitro Use Only | For Research Use Only | Not For Diagnostic Use



EMPIRE
GENOMICS

800.715.5880
3370 Walden Avenue Suite 114
Depew, NY 14043



IGH100
051625